scholarly journals The assessment of trabecular bone score to improve the sensitivity of FRAX in patients with type 2 diabetes mellitus

2020 ◽  
Vol 22 (4) ◽  
pp. 4-11
Author(s):  
Tatiana O. Yalochkina ◽  
Zhanna E. Belaya ◽  
Tatiana O. Chernova ◽  
Natalia I. Sazonova ◽  
Natalya V. Tarbaeva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Trabecular Bone ◽  
Trabecular Bone Score ◽  
Control Group ◽  
T Score ◽  
History Of ◽  
Probability Of Fracture ◽  
Frax Score

Aim. To estimate the trabecular bone score (TBS) for evaluation of fracture probability in order to make decisions about starting osteoporosis treatment in patients with type 2 diabetes mellitus (T2DM). Materials and methods. We obtained the bone mineral density (BMD) and trabecular bone score (TBS) using dual energy X-ray absorptiometry (iDXA) in patients with T2DM (with and without a history of osteoporotic fractures) versus the control group. Before and after TBS measurements we assessed the ten-year probability of fracture using the Fracture Risk Assessment Tool (FRAX). Results. We enrolled 48 patients with T2DM, including 17 with a history of low-traumatic fracture, 31 patients without fractures and 29 subjects of a control group. BMD was higher in patients with T2DM compared to the control group at L1L4 (mean T-score 0.44, 95% CI -3.2 4.9 vs mean T-score 0.33, 95% CI -2.9 3.0 in a control group p=0.052) and Total Hip (mean T-score 0.51, 95% CI -2.1 3.0 vs mean T-score -0.03, 95% CI -1.4 1.2 in a control group p=0,025). The TBS and 10-year probability of fracture (FRAX) was not different in patients with T2DM versus the control group. However, when the TBS was entered as an additional risk factor, the 10-year probability of fracture became higher in patients with T2DM (10-year probability of fracture in T2DM- 8.68, 95% CI 0.3-25.0 versus 6.68, 95% CI 0.415.0 in control group, p=0.04). Among patients with diabetes with and without fractures the FRAX score was higher in subjects with fractures, but no difference was found in regards to BMD or TBS. Entering BMD and TBS values into the FRAX tool in subjects with diabetes and fractures decreased the FRAX score. However, patients with low-traumatic fractures should be treated for osteoporosis without a BMD, TBS or FRAX assessment. Conclusion. TBS improves the results of FRAX assessment in patients with T2DM and should be entered while evaluating FRAX in patients with T2DM. However, additional research is needed to develop a more sensitive tool to evaluate fracture risk in patients with T2DM.

scholarly journals The assessment of Trabecular bone score to improve the sensitivity of FRAX in patients with type 2 diabetes mellitus

2017 ◽  
Vol 14 (4) ◽  
pp. 67-72 ◽  
Author(s):  
Tatiana O. Yalochkina ◽  
Zhanna E. Belaya ◽  
Tatiana O. Chernova ◽  
Natalia I. Sazonova ◽  
Natalia V. Tarbaeva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Trabecular Bone ◽  
Trabecular Bone Score ◽  
Control Group ◽  
T Score ◽  
History Of ◽  
Probability Of Fracture ◽  
Frax Score

Aim. To estimate the trabecular bone score (TBS) for evaluation of fracture probability in order to make decisions about starting osteoporosis treatment in patients with type 2 diabetes mellitus (T2DM). Materials and methods. We obtained the bone mineral density (BMD) and trabecular bone score (TBS) using dual energy X-ray absorptiometry (iDXA) in patients with T2DM (with and without a history of osteoporotic fractures) versus the control group. Before and after TBS measurements we assessed the ten-year probability of fracture using the Fracture Risk Assessment Tool (FRAX). Results. We enrolled 48 patients with T2DM, including 17 with a history of low-traumatic fracture, 31 patients without fractures and 29 subjects of a control group. BMD was higher in patients with T2DM compared to the control group at L1L4 (mean T-score 0.44, 95% CI -3.2 4.9 vs mean T-score 0.33, 95% CI -2.9 3.0 in a control group p=0.052) and Total Hip (mean T-score 0.51, 95% CI -2.1 3.0 vs mean T-score -0.03, 95% CI -1.4 1.2 in a control group p=0,025). The TBS and 10-year probability of fracture (FRAX) was not different in patients with T2DM versus the control group. However, when the TBS was entered as an additional risk factor, the 10-year probability of fracture became higher in patients with T2DM (10-year probability of fracture in T2DM- 8.68, 95% CI 0.3-25.0 versus 6.68, 95% CI 0.415.0 in control group, p=0.04). Among patients with diabetes with and without fractures the FRAX score was higher in subjects with fractures, but no difference was found in regards to BMD or TBS. Entering BMD and TBS values into the FRAX tool in subjects with diabetes and fractures decreased the FRAX score. However, patients with low-traumatic fractures should be treated for osteoporosis without a BMD, TBS or FRAX assessment. Conclusion. TBS improves the results of FRAX assessment in patients with T2DM and should be entered while evaluating FRAX in patients with T2DM. However, additional research is needed to develop a more sensitive tool to evaluate fracture risk in patients with T2DM.

Trabecular bone score and insulin resistance in type 2 diabetes mellitus

2020 ◽  
Author(s):  
Ponce Maria Hayon ◽  
Laguna Mª del Carmen Serrano ◽  
Perez Maria Dolores Aviles ◽  
Beatriz Garcia Fontana ◽  
Sheila Gonzalez Salvatierra ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Trabecular Bone ◽  
Trabecular Bone Score

Trabecular Bone Score in Thais with or without Type 2 Diabetes

2020 ◽  
Vol 103 (11) ◽  
pp. 1131-1137
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fracture Risk ◽  
Trabecular Bone ◽  
Trabecular Bone Score ◽  
Mineral Density ◽  
Men And Women

Background: When compared to people without type 2 diabetes mellitus (T2DM), people with T2DM have an increase in fracture risk despite having higher bone mineral density (BMD). Many studies in Caucasians demonstrated that trabecular bone score (TBS) is lower in people with T2DM than those without. The utility of TBS as a fracture risk assessment tool in Asians with T2DM is currently unclear. Objective: To compared lumbar spine (LS) BMD and TBS in Thais with or without T2DM and investigate the correlation between TBS and hemoglobin A1c (HbA1c) and diabetes duration in participants with T2DM. Materials and Methods: The present study was a cross-sectional study that included 97 participants with T2DM (37 men and 60 women) and 342 participants without T2DM (174 men and 168 women). LS-BMD and TBS were obtained. Results: Men and women with T2DM were older and had higher body mass index (BMI). Men with T2DM had significant higher LS-BMD (1.051±0.166 versus 0.972±0.125, p=0.009) and non-significant lower TBS (1.333±0.084 versus 1.365±0.096, p=0.055) than those without. Similarly, women with T2DM had significant higher LS-BMD (0.995±0.155 versus 0.949±0.124, p=0.021) and lower TBS (1.292±0.105 versus 1.382±0.096, p<0.001). After adjusting for age and BMI, T2DM predicted higher BMD in men (p<0.001), but not in women (p=0.143). T2DM was not associated with TBS after adjusting for age and BMI in both genders (p=0.403 and p=0.151 in men and women, respectively). TBS did not correlate with HbA1c in both genders. However, TBS was non-significantly associated with diabetes duration in women (p=0.073), but not in men (p=0.639). Conclusion: T2DM significantly predicted higher LS-BMD only in men and was not independently associated with TBS in both genders. These data highlighted that, in T2DM, there was some variation in the clinical usefulness of BMD and TBS in predicting osteoporotic fractures with regard to clinical characteristic of participants. Keywords: Bone mineral density, Type 2 diabetes mellitus, Trabecular bone score

Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort

2019 ◽  
Vol 73 (5) ◽  
pp. e13347 ◽  
Author(s):  
Felicia Baleanu ◽  
Pierre Bergmann ◽  
Anne Sophie Hambye ◽  
Carole Dekelver ◽  
Laura Iconaru ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Trabecular Bone ◽  
Bone Quality ◽  
Trabecular Bone Score

Clinical assessment of trabecular bone microstructure in type 2 diabetes mellitus with Trabecular Bone Score (TBS)

2017 ◽  
Author(s):  
Maria Dolores Aviles Perez ◽  
Antonia Garcia Martin ◽  
Cristina Novo Rodriguez ◽  
Rafael Nieto Serrano ◽  
Elena Torres Vela ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Trabecular Bone ◽  
Clinical Assessment ◽  
Trabecular Bone Score ◽  
Bone Microstructure ◽  
Trabecular Bone Microstructure

scholarly journals Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Sachiko Hattori
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cell Function ◽  
Urinary Albumin ◽  
Control Group ◽  
Β Cell ◽  
Glucose Lowering ◽  
Β Cell Function ◽  
History Of

Abstract Background Early and effective intervention with a dipeptidyl peptidase 4 inhibitor (DPP4i) before the development of advanced atherosclerosis in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease (CVD) is reported to increase the chance of significant reductions in not only microvascular disease, but also CVD. Method This study aimed to investigate whether sitagliptin is effective and tolerated for glycemic control and whether renoprotective effects and β-cell function are preserved for as long as ten years in Japanese patients with T2DM without a history of CVD. Results The situation is equivalent to improving glycemic control as assessed by hemoglobin A1c both in a sitagliptin group [sitagliptin 50 mg as either monotherapy or combination therapy with other oral glucose-lowering drugs (n = 17)] or a control group [placebo as either monotherapy or combination therapy with other glucose-lowering drugs (n = 9)], while anti-inflammatory effects as assessed by high-sensitivity C-reactive peptide in the sitagliptin group were superior to those in the control group. In the sitagliptin group, mean urinary albumin excretion (measured as urinary albumin-to-creatinine ratio) was markedly decreased, but no changes in estimated glomerular filtration rate were seen throughout the study. Beta-cell function as evaluated by homeostatic model assessment of β-cell function values was reduced at baseline in both groups, improved significantly in the sitagliptin group, and continued unchanged in the control group during the study. Conclusion These observations suggest that early intervention with sitagliptin in patients with T2DM may have long-lasting renoprotective and islet-protective effects. Trial registration: UMIN Clinical Registry (UMIN000038459). Registered 01 November (retrospectively registered): https://upload.umin.ac.jp/UMIN000038459

Relationship between muscle function and trabecular bone score (TBS) in Type 2 diabetes mellitus

2021 ◽  
Author(s):  
Maria Hayon Ponce ◽  
David Blanquez Martinez ◽  
del Carmen Serrano Laguna Mª ◽  
Dolores Aviles Perez Maria ◽  
Beatriz Garcia Fontana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Trabecular Bone ◽  
Muscle Function ◽  
Trabecular Bone Score

Lower trabecular bone score in type 2 diabetes mellitus: a role for fat mass and insulin resistance beyond hyperglycaemia

2021 ◽  
pp. 101276
Author(s):  
María Hayón-Ponce ◽  
Beatriz García-Fontana ◽  
María Dolores Avilés-Pérez ◽  
Sheila González-Salvatierra ◽  
Francisco Andújar-Vera ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Trabecular Bone ◽  
Fat Mass ◽  
Trabecular Bone Score
Sign in / Sign up

Export Citation Format

Share Document